Visit our Homepage

Scientific Program Highlights: Biomarkers

Treatment stratification by PET/CT has improved outcome and reduced treatment toxicity in Hodgkin Lymphoma. Recently, results of the GHSG HD18 trial were presented at EHA 2017. In this study, treatment stratification by PET/CT allowed reducing treatment duration to 4 cycles in most advanced stage patients with excellent efficacy. In the future, DNA, RNA or protein based biomarkers might play a similar role by allowing stratification of patients into biological risk groups and making measurement of minimal residual disease possible. Current technological advances increase the sensitivity of liquid biopsies to detect genetic abnormalities in many diseases. We are excited to see how these technologies will in uence the treatment of Hodgkin Lymphoma in the future.

The clinical relevance of some biomarkers such as TARC or specific microRNAs needs to be established. In addition, new technologies allow the evaluation of new biomarkers. We look forward to see more data in the near future in this exciting area.

Might also be interesting

Developments in Advanced Stages

Latest Results of Large Scale Randomized Phase Ⅲ Trials in Advanced Stage HL

One central question in Hodgkin Lymphoma is the best treatment for advanced stage patients. Initial data of the company-sponsored international ECHELON-1 trial were expected with substantial interest and will be presented at ASH 2017 in detail…

Read more…


Abstract Submission

Presenting your research at ISHL11 is a powerful way to gain international recognition, valuable feedback from colleagues and to make important connections...

Read more…

Read the corresponding E-Mail

Organisation

Andreas Engert, MD
Symposium Chairman

Sven Borchmann, MD
Congress Secretary

Paul Bröckelmann, MD
Congress Secretary

Dennis Eichenauer, MD
Congress Secretary

German Hodgkin Study Group (GHSG)
University Hospital of Cologne
Kerpener Str. 62
D-50924 Köln